PRAF2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells

Wang,Yabing; Zhao,Zhiyong; Jiao,Wei; Yin,Zhaocai; Zhao,Wanjun; Bo,Hongguang; Bi,Zilin; Dong,Bingbin; Chen,Bin; Wang,Zheng

doi:10.3892/etm.2022.11674

PRAF2 is an oncogene acting to promote the proliferation and invasion of breast cancer cells

Authors:
- Yabing Wang
- Zhiyong Zhao
- Wei Jiao
- Zhaocai Yin
- Wanjun Zhao
- Hongguang Bo
- Zilin Bi
- Bingbin Dong
- Bin Chen
- Zheng Wang
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China, Department of Thyroid and Breast Surgery, The Second Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, P.R. China
Published online on: November 1, 2022 https://doi.org/10.3892/etm.2022.11674
Article Number: 738
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prenylated rab acceptor 1 domain family member 2 (PRAF2) acts as an oncogene and is closely related to the occurrence and development of various tumors. The present study aimed to clarify the functional relevance of PRAF2 in the biological behaviors of breast cancer by determining the expression of PRAF2 in breast cancer tissues and the corresponding adjacent tissues. The gene phenotypes of PRAF2 in patients with breast cancer in The Cancer Genome Atlas database were predicted using a cancer data online analysis website: The University of Alabama at Birmingham Cancer Data Analaysis Portal (UALCAN). The mRNA and protein expression of PRAF2 was further examined in 37 pairs of fresh frozen breast cancer tissues and adjacent non‑tumor tissues by reverse transcription‑quantitative PCR (RT‑qPCR) and western blotting. High expression of PRAF2 was verified by RT‑qPCR in the breast cancer cell line, MCF‑7, and small interfering RNA (siRNA) technology was used to silence PRAF2. In the in vitro cell functional experiment, three groups were used: Negative control (NC) group, siRNA‑NC group and siRNA‑PRAF2 group. Cell Counting Kit‑8 (CCK‑8) and colony formation assays were conducted to analyze the effect of downregulation of PRAF2 on the proliferation of breast cancer cells. Transwell invasion and cell scratch assays were performed to examine the effect of downregulation of PRAF2 on the invasion and migration of breast cancer cells. UALCAN analysis results indicated that PRAF2 expression was upregulated in breast cancer compared with normal tissue samples (P<0.001). High expression of PRAF2 in breast cancer was associated with TNM stage and regional lymph node metastasis. RT‑qPCR results showed increased mRNA expression of PRAF2 in clinical tissue samples from 37 patients with breast cancer, compared with normal adjacent tissues (P<0.001). Protein expression of PRAF2 was also shown to be higher in the breast cancer MCF‑7 cells than in the MDA‑MB‑231 cells. Western blotting analysis combined with ImageJ software quantification showed that the relative expression of PRAF2 protein was significantly higher in clinical tissue samples from 37 patients with breast cancer (1.9750±0.0103) than that in normal adjacent tissues (0.9818±0.0140) (P<0.001). Western blotting analysis results indicated that transfection with siRNA PRAF2 in MCF‑7 cells decreased PRAF2 expression (P<0.001). The results of CCK‑8 and colony formation assays revealed that downregulation of PRAF2 expression suppressed the proliferation of MCF‑7 cells (P<0.05 and P<0.001, respectively). In addition, Transwell invasion and cell scratch assay results showed that downregulation of PRAF2 expression in MCF‑7 cells repressed invasion and migration of cancer cells (P<0.001). Overall, PRAF2 expression was significantly higher in breast cancer tissues than normal adjacent tissues, and was closely related to TNM stage and regional lymph node metastasis in breast cancer. PRAF2 was found to act as an oncogene that is able to promote breast cancer cell proliferation and invasion. Thus, PRAF2 may be a potential prognostic factor in patients with breast cancer and a potential target for the treatment of breast cancer metastasis.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.PubMed/NCBI View Article : Google Scholar
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
4	Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.PubMed/NCBI View Article : Google Scholar
5	Ruggiero AM, Liu Y, Vidensky S, Maier S, Jung E, Farhan H, Robinson MB, Sitte HH and Rothstein JD: The endoplasmic reticulum exit of glutamate transporter is regulated by the inducible mammalian Yip6b/GTRAP3-18 protein. J Biol Chem. 283:6175–6183. 2008.PubMed/NCBI View Article : Google Scholar
6	Doly S and Marullo S: Gatekeepers controlling GPCR export and function. Trends Pharmacol Sci. 36:636–644. 2015.PubMed/NCBI View Article : Google Scholar
7	Doly S, Shirvani H, Gäta G, Meye FJ, Emerit MB, Enslen H, Achour L, Pardo-Lopez L, Yang SK, Armand V, et al: GABAB receptor cell-surface export is controlled by an endoplasmic reticulum gatekeeper. Mol Psychiatry. 21:480–490. 2016.PubMed/NCBI View Article : Google Scholar
8	Fo CS, Coleman CS, Wallick CJ, Vine AL and Bachmann AS: Genomic organization, expression profile, and characterization of the new protein PRA1 domain family, member 2 (PRAF2). Gene. 371:154–165. 2006.PubMed/NCBI View Article : Google Scholar
9	Kim JT, Cho MY, Choi SC, Kim JW, Chae SK, Yoon DY, Kim JW and Lim JS: Prenylated Rab acceptor 1 (PRA1) inhibits TCF/beta-catenin signaling by binding to beta-catenin. Biochem Biophys Res Commun. 349:200–208. 2006.PubMed/NCBI View Article : Google Scholar
10	Chen Y, Huang Y, Huang Y, Xia X, Zhang J, Zhou Y, Tan Y, He S, Qiang F, Li A, et al: JWA suppresses tumor angiogenesis via Sp1-activated matrix metalloproteinase-2 and its prognostic significance in human gastric cancer. Carcinogenesis. 35:442–451. 2014.PubMed/NCBI View Article : Google Scholar
11	Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, Wu Y, Gong Z, Li A, Xu S, et al: JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene. 29:1227–1237. 2010.PubMed/NCBI View Article : Google Scholar
12	Chen H, Bai J, Ye J, Liu Z, Chen R, Mao W, Li A and Zhou J: JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. Cell Signal. 19:1315–1327. 2007.PubMed/NCBI View Article : Google Scholar
13	Geerts D, Wallick CJ, Koomoa DL, Koster J, Versteeg R, Go RC and Bachmann AS: Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: Correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Clin Cancer Res. 13:6312–6319. 2007.PubMed/NCBI View Article : Google Scholar
14	Brodeur GM, Seeger RC, Schwab M, Varmus HE and Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 224:1121–1124. 1984.PubMed/NCBI View Article : Google Scholar
15	Yco LP, Geerts D, Koster J and Bachmann AS: PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma. Int J Oncol. 42:1408–1416. 2013.PubMed/NCBI View Article : Google Scholar
16	Borsics T, Lundberg E, Geerts D, Koomoa DL, Koster J, Wester K and Bachmann AS: Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: Influence on cell survival and migration. Cancer Sci. 101:1624–1631. 2010.PubMed/NCBI View Article : Google Scholar
17	Wang CH, Liu LL, Liao DZ, Zhang MF, Fu J, Lu SX, Chen SL, Wang H, Cai SH, Zhang CZ, et al: PRAF2 expression indicates unfavorable clinical outcome in hepatocellular carcinoma. Cancer Manag Res. 10:2241–2248. 2018.PubMed/NCBI View Article : Google Scholar
18	Qian Z, Wei B, Zhou Y, Wang Q, Wang J, Sun Y, Gao Y and Chen X: PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma. BMC Cancer. 19(585)2019.PubMed/NCBI View Article : Google Scholar
19	Chen X, Feng J, Ge Z, Chen H, Ding W, Zhu W, Tang X, Chen Y, Tan Y and Ma T: Effects of the JWA gene in the regulation of human breast cancer cells. Mol Med Rep. 11:3848–3853. 2015.PubMed/NCBI View Article : Google Scholar
20	Xu L, Cheng L, Yang F, Pei B, Liu X, Zhou J, Zhu Y and Wang S: JWA suppresses the invasion of human breast carcinoma cells by downregulating the expression of CXCR4. Mol Med Rep. 17:8137–8144. 2018.PubMed/NCBI View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
22	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017.PubMed/NCBI View Article : Google Scholar
23	Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008.PubMed/NCBI View Article : Google Scholar
24	Grebić D, Pirjavec A, Kustić D and Klarica Gembić T: Surgical treatment for breast cancer and axillary metastases: Historical perspective. Acta Med Hist Adriat. 19:125–136. 2021.PubMed/NCBI View Article : Google Scholar
25	Maughan KL, Lutterbie MA and Ham PS: Treatment of breast cancer. Am Fam Physician. 81:1339–1346. 2010.PubMed/NCBI
26	Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP and Cardoso F: ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: Can metastatic breast cancer be cured? J Natl Cancer Inst. 102:456–463. 2010.PubMed/NCBI View Article : Google Scholar
27	Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S and Senkus E: ESMO Guidelines Committee. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 30:1194–1220. 2019.PubMed/NCBI View Article : Google Scholar
28	Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, et al: Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 317:2402–2416. 2017.PubMed/NCBI View Article : Google Scholar
29	Kouno J, Nagai H, Nagahata T, Onda M, Yamaguchi H, Adachi K, Takahashi H, Teramoto A and Emi M: Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth. J Neurooncol. 70:301–307. 2004.PubMed/NCBI View Article : Google Scholar
30	Roos WP, Thomas AD and Kaina B: DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 16:20–33. 2016.PubMed/NCBI View Article : Google Scholar
31	Spill F, Reynolds DS, Kamm RD and Zaman MH: Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 40:41–48. 2016.PubMed/NCBI View Article : Google Scholar
32	Wan L, Pantel K and Kang Y: Tumor metastasis: Moving new biological insights into the clinic. Nat Med. 19:1450–1464. 2013.PubMed/NCBI View Article : Google Scholar
33	Kozłowski J, Kozłowska A and Kocki J: Breast cancer metastasis-insight into selected molecular mechanisms of the phenomenon. Postepy Hig Med Dosw (Online). 69:447–451. 2015.PubMed/NCBI View Article : Google Scholar
34	Schweneker M, Bachmann AS and Moelling K: JM4 is a four-transmembrane protein binding to the CCR5 receptor. FEBS Lett. 579:1751–1758. 2005.PubMed/NCBI View Article : Google Scholar
35	Lu J, Tang Y, Farshidpour M, Cheng Y, Zhang G, Jafarnejad SM, Yip A, Martinka M, Dong Z, Zhou J, et al: JWA inhibits melanoma angiogenesis by suppressing ILK signaling and is an independent prognostic biomarker for melanoma. Carcinogenesis. 34:2778–2788. 2013.PubMed/NCBI View Article : Google Scholar
36	Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu C, Wang C and Ye L: Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 6(307)2021.PubMed/NCBI View Article : Google Scholar
37	Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, Zhou Z, Shu G and Yin G: Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 7(3)2022.PubMed/NCBI View Article : Google Scholar
38	He W, Tang J, Li W, Li Y, Mei Y, He L, Zhong K and Xu R: Mutual regulation of JAG2 and PRAF2 promotes migration and invasion of colorectal cancer cells uncoupled from epithelial-mesenchymal transition. Cancer Cell Int. 19(160)2019.PubMed/NCBI View Article : Google Scholar